Biotechnology
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.

$595.3M

Market Cap • 12/26/2024

2014

(10 years)
Founded

2019

(5 years ago)
IPO

NASDAQ

Listing Exchange
Flag of US

Bedford

Headquarters • Massachusetts